The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An 18F-MISO PET-MRI Study

被引:11
|
作者
Mainta, Ismini C. [1 ]
Zilli, Thomas [2 ,3 ]
Tille, Jean-Christophe [4 ]
De Perrot, Thomas [5 ]
Vallee, Jean-Paul [3 ,5 ]
Buchegger, Franz [1 ,3 ]
Garibotto, Valentina [1 ,3 ]
Miralbell, Raymond [2 ,3 ]
机构
[1] Geneva Univ Hosp, Nucl Med & Mol Imaging, Geneva, Switzerland
[2] Geneva Univ Hosp, Radiat Oncol, Rue Gabrielle Perret Gentil 4, CH-1211 Geneva 14, Switzerland
[3] Univ Geneva, Fac Med, Geneva, Switzerland
[4] Geneva Univ Hosp, Clin Pathol, Geneva, Switzerland
[5] Geneva Univ Hosp, Radiol, Geneva, Switzerland
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2018年 / 102卷 / 04期
关键词
CONTRAST-ENHANCED-MRI; OXYGENATION STATUS; UTERINE-CERVIX; RAT PROSTATE; RADIOTHERAPY; EXPRESSION; MICROENVIRONMENT; PERFUSION; F-18-FLUOROMISONIDAZOLE; OVEREXPRESSION;
D O I
10.1016/j.ijrobp.2018.02.170
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Tumor hypoxia is associated with radioresistance and poor prognosis after radiation therapy for prostate cancer (PCa). In this prospective pilot study, we assessed the ability of F-18-misonidazole (F-18-MISO) positron emission tomography (PET)-magnetic resonance imaging (MRI) to detect hypoxia in high-grade PCa patients who were candidates for curative radiation therapy, and we evaluated F-18-MISO PET-MRI modulation after 3 months of neoadjuvant androgen deprivation therapy (nADT). Methods and Materials: Eleven PCa patients with a Gleason score (GS) >= 8 underwent F-18-fluorocholine (F-18-FCH) PET-computed tomography at diagnosis and an F-18-MISO hybrid PET-MRI examination before nADT; a second F-18-MISO PET-MRI examination was acquired after 3 months of nADT for all patients but one who dropped out because of noncompliance with nADT. Immunohistochemistry for tissue hypoxia-and proliferation-related biomarkers (glucose transporter 1, carbonic anhydrase IX, vascular endothelial growth factor A, Ki-67, hypoxia-inducible factor 1 alpha, and epidermal growth factor receptor) was performed in lesions bearing the highest GS. We used nonparametric tests to assess (1) the presence of F-18-MISO-positive regions (tumor-to-background ratio [TBR] >= 1.4) at baseline; (2) the correlation between imaging parameters (PET tracer uptake, Prostate Imaging Reporting and Data System [PIRADS] scores, and dynamic contrast enhancement perfusion markers) at baseline; (3) the difference in immunohistochemistry staining between F-18-MISO-positive and -negative lesions; and (4) the changes in F-18-MISO PET-MRI after nADT. Results: Uptake of F-18-MISO was significant in 7 patients, being coincidental with the highest GS region in 5 of them. A significant correlation was found at baseline between GS and F-18-MISO TBR, between F-18-MISO TBR and MRI perfusion markers, between GS and F-18-FCH maximum standardized uptake value, between GS and PIRADS score, and between F-18-FCH maximum standardized uptake value and PIRADS score. No difference was found between F-18-MISO-positive and -negative biopsy specimens with respect to tissue biomarkers. The TBR of F-18-MISO diminished significantly after nADT only in high-grade lesions and in regions with a significant uptake at baseline. Conclusions: PET imaging with F-18-MISO showed variable uptake in PCa, associated with a higher GS, lowering significantly after 3 months of nADT in high-grade lesions. These results suggest the existence of a hypoxic microenvironment in PCa and a reoxygenation effect of nADT. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:1210 / 1218
页数:9
相关论文
共 12 条
  • [1] Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer
    Wang, Chenyang
    Raldow, Ann C.
    Nickols, Nicholas G.
    Nguyen, Paul L.
    Spratt, Daniel E.
    Dess, Robert T.
    Yu, James B.
    King, Christopher R.
    Chu, Fang-, I
    Chamie, Karim
    Litwin, Mark S.
    Saigal, Christopher S.
    Reiter, Robert E.
    Liu, Sandy T.
    Rettig, Matthew B.
    Chang, Albert J.
    Steinberg, Michael L.
    Kupelian, Patrick A.
    Kishan, Amar U.
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02): : 327 - 330
  • [2] 18F-FAZA PET imaging in tumor hypoxia: A focus on high-grade glioma
    Mapelli, Paola
    Picchio, Maria
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2020, 35 (1_SUPPL) : 42 - 46
  • [3] 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy
    Malviya, Gaurav
    Patel, Rachana
    Salji, Mark
    Martinez, Rafael S.
    Repiscak, Peter
    Mui, Ernest
    Champion, Susan
    Mrowinska, Agata
    Johnson, Emma
    AlRasheedi, Maha
    Pimlott, Sally
    Lewis, David
    Leung, Hing Y.
    EJNMMI RESEARCH, 2020, 10 (01)
  • [4] Hypoxia 18F-FAZA PET/CT imaging in lung cancer and high-grade glioma: open issues in clinical application
    Mapelli, P.
    Incerti, E.
    Bettinardi, V.
    Conte, G. M.
    Fallanca, F.
    Bailo, M.
    Vuozzo, M.
    Callea, M.
    Gianolli, L.
    Picchio, M.
    CLINICAL AND TRANSLATIONAL IMAGING, 2017, 5 (04) : 389 - 397
  • [5] Validation of 18F-FDG PET at Conventional and Delayed Intervals for the Discrimination of High-Grade From Low-Grade Gliomas A Stereotactic PET and MRI Study
    Mertens, Koen
    Acou, Marjan
    Van Hauwe, Jel
    De Ruyck, Ine
    Van den Broecke, Caroline
    Kalala, Jean-Pierre Okito
    D'Asseler, Yves
    Goethals, Ingeborg
    CLINICAL NUCLEAR MEDICINE, 2013, 38 (07) : 495 - 500
  • [6] A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy
    Christie, David R. H.
    Mitina, Natalia
    Sharpley, Christopher F.
    CURRENT UROLOGY, 2021, 15 (01) : 63 - 67
  • [7] [18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial
    Glicksman, Rachel M.
    Metser, Ur
    Valliant, John
    Chung, Peter W.
    Fleshner, Neil E.
    Bristow, Robert G.
    Green, David
    Finelli, Antonio
    Hamilton, Robert
    Stanescu, Teodor
    Hussey, Douglas
    Catton, Charles
    Gospodarowicz, Mary
    Warde, Padraig
    Bayley, Andrew
    Breen, Stephen
    Vines, Doug
    Jaffray, David A.
    Berlin, Alejando
    BMJ OPEN, 2020, 10 (04):
  • [8] Impact of 18F-fluciclovine PET/CT on plans for androgen deprivation therapy in patients with biochemical recurrence of prostate cancer: data analysis from two prospective clinical trials
    Andriole, Gerald L.
    Scarsbrook, Andrew F.
    LOCATE FALCON Study Groups
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (06) : 293.e1 - 293.e7
  • [9] HYPOXIA, ANDROGEN DEPRIVATION AND SYSTEMIC METASTASES IN PROSTATE CANCER (IN RESPONSE TO "ANTIVASCULAR EFFECTS OF NEOADJUVANT ANDROGEN DEPRIVATION FOR PROSTATE CANCER: AN IN VIVO HUMAN STUDY USING SUSCEPTIBILITY AND RELAXITIVITY DYNAMIC MRI": IN REGARD TO ALONZI R ET AL. (INT J RADIAT ONCOL BIOL PHYS 2011;80(3):721-727)
    Dal Pra, Alan
    Milosevic, Michael
    Hill, Richard
    Wouters, Bradley
    Warde, Padraig
    Bristow, Robert G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 82 (04): : 1319 - 1319
  • [10] Intense Androgen-Deprivation Therapy With Abiraterone Acetate Plus Leuprolide Acetate in Patients With Localized High-Risk Prostate Cancer: Results of a Randomized Phase II Neoadjuvant Study
    Taplin, Mary-Ellen
    Montgomery, Bruce
    Logothetis, Christopher J.
    Bubley, Glenn J.
    Richie, Jerome P.
    Dalkin, Bruce L.
    Sanda, Martin G.
    Davis, John W.
    Loda, Massimo
    True, Lawrence D.
    Troncoso, Patricia
    Ye, Huihui
    Lis, Rosina T.
    Marck, Brett T.
    Matsumoto, Alvin M.
    Balk, Steven P.
    Mostaghel, Elahe A.
    Penning, Trevor M.
    Nelson, Peter S.
    Xie, Wanling
    Jiang, Zhenyang
    Haqq, Christopher M.
    Tamae, Daniel
    NamPhuong Tran
    Peng, Weimin
    Thian Kheoh
    Molina, Arturo
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) : 3705 - +